Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 6;217(7):e20191453. doi: 10.1084/jem.20191453

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tay et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — HDAC3 negatively regulates CD8 T cell cytotoxicity. (A and B) Cytotoxicity of in vitro activated RGFP966-treated (A) and Hdac3-KO (B) OT-I T cells against OVA-expressing B16 melanoma targets (B16-OVA). Data are representative of two independent experiments, each with four technical replicates per condition. (C) In vivo cytotoxicity of adoptively transferred Hdac3-KO and Hdac3-WT OT-I T cells against OVA peptide–pulsed target cells. Data are representative of two independent experiments with seven host mice for each genotype of transferred donor OT-I T cells. (D) Experimental scheme of OVA immunization (Imm.) experiments following OT-I transfer. 5 × 10⁵ cells of a 1:1 mix of congenically distinct Hdac3-KO (E8I-Cre⁺; Hdac3^fl/fl) and Hdac3-WT OT-I T cells were transferred into CD45.1⁺ TCR-polyclonal recipients. Alternatively, 5 × 10⁵ cells of a 1:1 mix of congenically distinct Hdac3-iKO (UBC-Cre-ERT2⁺; Hdac3^fl/fl) and Hdac3-WT OT-I T cells were transferred, and 2 mg of tamoxifen (Tam.) was administered daily for 3 d to induce Cre-mediated inactivation of Hdac3. Mice were immunized subcutaneously with OVA + poly(I:C) in PBS. (E and F) Flow-cytometric analysis (E) and quantification (F) of markers of effector phenotype of Hdac3-WT and Hdac3-KO OT-I T cells in inguinal LNs draining the immunization site harvested 4 d after immunization as in D. Data are representative of two independent experiments with five recipient mice each. Data from cotransferred donor cells of each genotype within the same recipient mouse were analyzed as pairs. (G and H) Flow-cytometric analysis (G) and quantification (H) of markers of effector phenotype of Hdac3-WT and Hdac3-iKO (Hdac3-inducible knockout) OT-I T cells in inguinal LNs draining the immunization site harvested 4 d after immunization as in D. Data are representative of two independent experiments with five recipient mice each. Data from cotransferred donor cells of each genotype within the same recipient mouse were analyzed as pairs. Means ± SD are indicated (A–C). P values were calculated by two-way ANOVA (A and B), two-tailed Student’s t test (C), or two-tailed ratio-paired t test (F and H). *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001.